Trimerbody formating services

The plug-and-play nature of LeadArtis technology enables the rapid creation of more powerful, more effective antibodies by simply incorporating the binding domains of pre-existing antibodies to the selected Trimerbody scaffold of our structure-based design. So far, all selected antigen binding domains incorporated into the Trimerbody scaffold have dramatically enhanced biological function compared to the parental antibody. A growing pipeline could be based on this approach to creating differentiated antibody drug candidates.
LeadArtis’s broad portfolio of Trimerbody formats are compatible with nearly any conventional antibody, single domain antibody or antibody mimetic. Trimerbody formatting provides enhanced performance in therapeutic antibody programs in preclinical and clinical development for the treatment of cancer, inflammatory and autoimmune disorders.
LeadArtis extends the use of the Trimerbody technology through licenses to interested partners. For instance, some partners advancing programs in clinical trials and numerous pre-clinical projects might consider Trimerbody as a backup program to reduce toxicity, extend circulatory half-life, improve stability and solubility, or add new binding domains (e.g. addition of tumor targeting) 

Latest News

LeadArtis participates in the fourth Immunostimulatory Agonist Antibodies for Cancer Therapy (IACT) meeting in London (UK)

The fourth IACT review meeting took place on October 25-26, 2017 in London, United Kingdom....

LeadArtis discloses ATTACK, a novel bispecific T cell-recruiting antibody approach for cancer immunotherapy

LeadArtis´scientists, in collaboration with other prime...

Leadartis successfully accomplishes the TERET project

Leadartis is proud to announce the successful conclusion of the TERET (New Treatments for...